RxDoctor Payments Data

Daniel Marion, MD

Internal Medicine · Chesterfield, MONPI 1275875908

Payments from drug & device makers

$14,517in general payments, 2019–2025

Across 866 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$2K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Pfizer$1K
  • Novo Nordisk$1K
  • plus $7K from 40 others

What the payments were for

  • Food & beverage$14,38099%
  • Education$1371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,517 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$202,132
Medicare patients
631
Services billed
1,941

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban255$318,514
FarxigaDapagliflozin Propanediol186$208,950
MounjaroTirzepatide140$194,996
JardianceEmpagliflozin126$156,690
Trelegy ElliptaFluticasone/Umeclidin/Vilanter120$115,942
OzempicSemaglutide63$100,483
EntrestoSacubitril/Valsartan89$97,233
LinzessLinaclotide76$75,649
MyrbetriqMirabegron65$63,135
XareltoRivaroxaban51$59,112
TrulicityDulaglutide21$44,100
GlyxambiEmpagliflozin/Linagliptin27$37,255
ArexvyRsvpref3 Antigen/As01e/Pf139$34,541
Repatha SureclickEvolocumab23$29,191
Trijardy XrEmpaglifloz/Linaglip/Metformin36$27,653

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,016$318,514255 claims
Boehringer IngelheimJardiance, Glyxambi, Trijardy Xr, Tradjenta$500$239,345206 claims
Lilly USA, LLCMounjaro, Trulicity$1,129$239,097161 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,693$228,865218 claims
GSKTrelegy Ellipta, Arexvy, Breo Ellipta$1,550$165,847294 claims
Novo NordiskOzempic$1,014$100,48363 claims
NovartisEntresto$520$97,23389 claims
AbbVieLinzess, Synthroid$1,409$82,360162 claims
Astellas Pharma US IncMyrbetriq$405$63,13565 claims
Johnson & JohnsonXarelto$301$59,11251 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Chesterfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →